John Saharek
Corporate Officer/Principal at HARROW, INC.
Net worth: 2 M $ as of 30/04/2024
Profile
John P.
Saharek is currently the President & Chief Executive Officer at ImprimisRx LLC since 2012 and the Chief Commercial Officer at Harrow, Inc. since 2012.
Previously, he worked as the Vice President-Business Development at Surmodics, Inc. from 2006 to 2011.
He also held the position of Head-US Marketing & Strategy at Thrombogenics, Inc. Mr. Saharek completed his undergraduate degree at Central Connecticut State University and obtained an MBA from the University of Hartford.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
HARROW, INC.
0.71% | 16/04/2024 | 249,803 ( 0.71% ) | 2 M $ | 30/04/2024 |
John Saharek active positions
| Companies | Position | Start |
|---|---|---|
| HARROW, INC. | Corporate Officer/Principal | 01/02/2015 |
| ImprimisRx LLC | Chief Executive Officer | 02/01/2024 |
Former positions of John Saharek
| Companies | Position | End |
|---|---|---|
| SURMODICS, INC. | Corporate Officer/Principal | 01/07/2011 |
Thrombogenics, Inc.
 Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The private company is based in New York, NY. | Sales & Marketing | - |
Training of John Saharek
| University of Hartford | Masters Business Admin |
| Central Connecticut State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| HARROW, INC. | Health Technology |
| SURMODICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Thrombogenics, Inc.
Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The private company is based in New York, NY. | Commercial Services |
| ImprimisRx LLC |
- Stock Market
- Insiders
- John Saharek